Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
blood cancer
Biotech
Silence brings the noise to Takeda with phase 2 blood cancer win
A phase 2 trial of Silence’s divesiran hit its primary endpoint, emboldening the biotech to advance a potential challenger to Takeda’s rusfertide.
Nick Paul Taylor
Aug 10, 2026 7:31am
Predicta links with Spanish university to offer blood cancer dx
Jun 11, 2026 8:13am
Roche bets $700M upfront on Nurix’s late-phase BTK degrader
Jun 8, 2026 4:41am
Aptose exits cancer pact after Hanmi buyout blocks development
May 14, 2026 6:35am
Fierce Pharma
FDA delays decision on Orca Bio’s cell therapy for blood cancers
Apr 1, 2026 8:00am
Fierce Pharma
Orca rides $250M funding wave toward cancer cell therapy launch
Jan 9, 2026 11:19am
